Clearmind Medicine (Clearmind Medicine) LT-Debt-to-Total-Asset : 0.00 (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Clearmind Medicine's long-term debt to total assests ratio for the quarter that ended in Jan. 2024 was 0.00.

Clearmind Medicine's long-term debt to total assets ratio increased from Jan. 2023 (0.00) to Jan. 2024 (0.00). It may suggest that Clearmind Medicine is progressively becoming more dependent on debt to grow their business.

Clearmind Medicine LT-Debt-to-Total-Asset Historical Data

The historical data trend for Clearmind Medicine's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine LT-Debt-to-Total-Asset Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Clearmind Medicine Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Clearmind Medicine LT-Debt-to-Total-Asset Calculation

Clearmind Medicine's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Oct. 2023 is calculated as

LT Debt to Total Assets (A: Oct. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Oct. 2023 )	/	Total Assets (A: Oct. 2023 )
	=	0	/	4.305
	=

Clearmind Medicine's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2024 is calculated as

LT Debt to Total Assets (Q: Jan. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jan. 2024 )	/	Total Assets (Q: Jan. 2024 )
	=	0.031	/	10.098
	=

Clearmind Medicine (NAS:CMND) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Clearmind Medicine LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearmind Medicine (Clearmind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

CWY0:Germany CWY0:Germany CMND:Canada

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.